Curio Wealth LLC Acquires 1,098 Shares of Pfizer Inc. $PFE

Curio Wealth LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 36,600.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,101 shares of the biopharmaceutical company’s stock after buying an additional 1,098 shares during the quarter. Curio Wealth LLC’s holdings in Pfizer were worth $27,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Bessemer Group Inc. increased its position in Pfizer by 11.1% in the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock valued at $3,358,000 after buying an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK grew its stake in Pfizer by 1.2% in the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock valued at $35,817,000 after acquiring an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp acquired a new position in shares of Pfizer during the first quarter worth approximately $8,283,000. Westbourne Investments Inc. bought a new position in shares of Pfizer in the 1st quarter worth $2,411,000. Finally, Bourne Lent Asset Management Inc. grew its position in Pfizer by 90.8% in the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after purchasing an additional 18,200 shares during the period. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PFE. Morgan Stanley dropped their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Saturday. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Bank of America raised their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.13.

Pfizer Stock Up 0.5%

PFE stock opened at $24.79 on Friday. The stock has a fifty day moving average of $24.87 and a 200-day moving average of $24.18. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.17. The company has a market capitalization of $140.92 billion, a price-to-earnings ratio of 13.18, a PEG ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.